



Report Number:	20-002237/D04.R00
Report Date:	03/04/2020
ORELAP#:	OR100028
Purchase Order:	
Received:	02/26/20 11:00

Customer:	Rogue Biosciences
Product identity:	NDT20003-CC
Client/Metrc ID:	
Laboratory ID:	20-002237-0003

Summary

91.5%
<pre><loq< pre=""></loq<></pre>
~LOQ
d in percent of total sample)
,

All analytes passing and less than LOQ.

Microbiology:

_ _

Less than LOQ for all analytes.

www.columbialaboratories.com





Report Number:	20-002237/D04.R00
Report Date:	03/04/2020
ORELAP#:	OR100028
Purchase Order:	
Received:	02/26/20 11:00

Customer:	Rogue Biosciences
Product identity:	NDT20003-CC
Client/Metrc ID:	
Sample Date:	
Laboratory ID:	20-002237-0003
Relinquished by:	UPS
Temp:	20.7 °C

Sample Results

Potency	Method J AOAC 201	5 V98-6	Units %	Batch 2002014	Analyze 03/03/20 12:43 AM
Analyte	As Dry Received weig	LOQ Notes	5		
CBC [†]	< LOQ	0.0928			• CBD
CBC-A [†]	< LOQ	0.0928			• CBD-A
CBC-Total [†]	< LOQ	0.174			• CBG-A
CBD	55.0	0.928			
CBD-A	41.6	0.928			• CBG
CBD-Total	91.5	1.74			• CBDV
CBDV [†]	0.227	0.0928			• CBDV-A
CBDV-A [†]	0.176	0.0928			
CBDV-Total [†]	0.380	0.173			
CBG [†]	0.430	0.0928			
CBG-A [†]	1.00	0.0928			
CBG-Total [†]	1.31	0.173			
CBL [†]	< LOQ	0.0928			
CBN	< LOQ	0.0928			
$\Delta 8\text{-THC}^{\dagger}$	< LOQ	0.0928			
∆9-THC	< LOQ	0.0928			
THC-A	< LOQ	0.0928			
THC-Total	< LOQ	0.174			
THCV [†]	< LOQ	0.0928			
THCV-A [†]	< LOQ	0.0928			
THCV-Total [†]	< LOQ	0.173			
Microbiology					
	D 14				n

AnalyteResultLimitsUnitsLOQBatchAnalyzeMethodNotesMold (RAPID Petrifilm)< LOQcfu/g10200185702/29/20AOAC 2014.05 (RAPID)XVeact (RAPID Petrifilm)< LOQcfu/g10200185702/29/20AOAC 2014.05 (RAPID)X	wicrobiology								
	Analyte	Result	Limits	Units	LOQ	Batch	Analyze	Method	Notes
Vesst (RAPID Petrifilm) < I OO cfu/a 10 2001857 02/20/20 AOAC 2014 05 (RAPID) X	Mold (RAPID Petrifilm)	< LOQ		cfu/g	10	2001857	02/29/20	AOAC 2014.05 (RAPID)	Х
	Yeast (RAPID Petrifilm)	< LOQ		cfu/g	10	2001857	02/29/20	AOAC 2014.05 (RAPID)	Х

www.columbialaboratories.com





 Report Number:
 20-002237/D04.R00

 Report Date:
 03/04/2020

 ORELAP#:
 OR100028

 Purchase Order:
 Received:

 02/26/20 11:00

Pesticides	Method	AOAC	2007.01 & EN	15662 (mod)	Units mg/kg Ba	tch 2001936	Analy	ze 02/29/20 10:02 AM
Analyte	Result	Limits	s LOQ Status	Notes	Analyte	Result	Limits	SLOQ Status Notes
Abamectin	< LOQ	0.50	0.250 pass		Acephate	< LOQ	0.40	0.250 pass
Acequinocyl	< LOQ	2.0	1.00 pass		Acetamiprid	< LOQ	0.20	0.100 pass
Aldicarb	< LOQ	0.40	0.200 pass		Azoxystrobin	< LOQ	0.20	0.100 pass
Bifenazate	< LOQ	0.20	0.100 pass		Bifenthrin	< LOQ	0.20	0.100 pass
Boscalid	< LOQ	0.40	0.200 pass		Carbaryl	< LOQ	0.20	0.100 pass
Carbofuran	< LOQ	0.20	0.100 pass		Chlorantraniliprole	< LOQ	0.20	0.100 pass
Chlorfenapyr	< LOQ	1.0	0.500 pass		Chlorpyrifos	< LOQ	0.20	0.100 pass
Clofentezine	< LOQ	0.20	0.100 pass		Cyfluthrin	< LOQ	1.0	0.500 pass
Cypermethrin	< LOQ	1.0	0.500 pass		Daminozide	< LOQ	1.0	0.500 pass
Diazinon	< LOQ	0.20	0.100 pass		Dichlorvos	< LOQ	1.0	0.500 pass
Dimethoate	< LOQ	0.20	0.100 pass		Ethoprophos	< LOQ	0.20	0.100 pass
Etofenprox	< LOQ	0.40	0.200 pass		Etoxazole	< LOQ	0.20	0.100 pass
Fenoxycarb	< LOQ	0.20	0.100 pass		Fenpyroximate	< LOQ	0.40	0.200 pass
Fipronil	< LOQ	0.40	0.200 pass		Flonicamid	< LOQ	1.0	0.400 pass
Fludioxonil	< LOQ	0.40	0.200 pass		Hexythiazox	< LOQ	1.0	0.400 pass
Imazalil	< LOQ	0.20	0.100 pass		Imidacloprid	< LOQ	0.40	0.200 pass
Kresoxim-methyl	< LOQ	0.40	0.200 pass		Malathion	< LOQ	0.20	0.100 pass
Metalaxyl	< LOQ	0.20	0.100 pass		Methiocarb	< LOQ	0.20	0.100 pass
Methomyl	< LOQ	0.40	0.200 pass		MGK-264	< LOQ	0.20	0.100 pass
Myclobutanil	< LOQ	0.20	0.100 pass		Naled	< LOQ	0.50	0.250 pass
Oxamyl	< LOQ	1.0	0.500 pass		Paclobutrazole	< LOQ	0.40	0.200 pass
Parathion-Methyl	< LOQ	0.20	0.200 pass		Permethrin	< LOQ	0.20	0.100 pass
Phosmet	< LOQ	0.20	0.100 pass		Piperonyl butoxide	e < LOQ	2.0	1.00 pass
Prallethrin	< LOQ	0.20	0.200 pass		Propiconazole	< LOQ	0.40	0.200 pass
Propoxur	< LOQ	0.20	0.100 pass		Pyrethrin I (total)	< LOQ	1.0	0.500 pass
Pyridaben	< LOQ	0.20	0.100 pass		Spinosad	< LOQ	0.20	0.100 pass
Spiromesifen	< LOQ	0.20	0.100 pass		Spirotetramat	< LOQ	0.20	0.100 pass
Spiroxamine	< LOQ	0.40	0.200 pass		Tebuconazole	< LOQ	0.40	0.200 pass
Thiacloprid	< LOQ	0.20	0.100 pass		Thiamethoxam	< LOQ	0.20	0.100 pass
Trifloxystrobin	< LOQ	0.20	0.100 pass					

www.columbialaboratories.com





 Report Number:
 20-002237/D04.R00

 Report Date:
 03/04/2020

 ORELAP#:
 OR100028

 Purchase Order:

 Received:
 02/26/20 11:00

These test results are representative of the individual sample selected and submitted by the client.

Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

[†] = Analyte not NELAP accredited.

Units of Measure

cfu/g = Colony forming units per gram mg/kg = Milligram per kilogram = parts per million (ppm) % = Percentage of sample % wt = μg/g divided by 10,000

Glossary of Qualifiers X: Not ORELAP accredited.

Approved Signatory

Derrick Tanner General Manager

www.columbialaboratories.com

Page 4 of 12

Columbia LABORATORIES 💽 A Tentamus Company

1 2 34

12423 NE Whitaker Way Portland, OR 97230 503-254-1794



Report Number: 20-002237/D04.R00 **Report Date:** 03/04/2020 **ORELAP#:** OR100028 Purchase Order: Received: 02/26/20 11:00

PIXIS Labs A Tentamus Company 12423 NE Whitaker Way Portland, OR 97230 Please inform us if you know or suspect that Phone: (503) 254-1794 Fax: (503) 254-1452 your sample contains hazardous chemicals. www.pixislabs.com customerservice@pixislabs.com **Chain of Custody Record** Company: Rogue Bioscience Testing Requested

Revision: 1.02 Document Control: CF001 Revision Date: 01/14/2019 Effective Date: 01/14/2019

20-002237

Some or all of this analyses may be subcontracted to an ORELAP accredited lab

Page 1 of 3

0	Anthony Del uca					1 -	1		restin	_ nequ	loteu				Purchase Ord	er: PO2	2520EFH			
1.						ast)														
City	y,State,Zip: Medford OR 97501					d/yea									Project Name	:				
Em	ail: testresults@emeraldfamilyher	mp.com																		
Pho	DT20002-SSC ' ' X X X X X Z ' Z Z <td< td=""><td></td></td<>																			
Bill		30 Auth/Check #																		
	Client Sample Identification				Poten	Microl									Sample Type	# Cnr	Comments			
ND	T20001-HH		2/25/20	9:45	x	x	x								oil	1	2.5 grams / non detect THC oil formulated with 40%CBDa/60%CBD			
ND	T20002-SSC		1	•	x	x	x			ч. Г					1	2	1			
ND	T20003-CC		1	1	x	х	x								1	3	1			
ND	T20004-L		1	1	x	x	x									4	I.			
Sar	npled by: Anthony DeLuca	* Reli	nquished b	y (Signat	ture) D		Date Time		ie	Received by (Signature)		Date		Time	Lab Use Only: Client Alias:					
Tu	rn-around time:	a	1.le	21		2/24	1/20	ド	05	Ha	zit	Al	on		2-26-20	11:00				
Asl	k for availability									2		,					Proper Container			
Z S	Standard		4.00			-														
	Rush (1.5 Times Standard)					-														
	Priority Rush (2 Times Standard)																Evidence of Cooling □Yes⊡ No			
																	Shipped Via: UPS			

*SUBMISSION OF SAMPLES WITH TESTING REQUIREMENTS TO PIXIS LABS WILL BE UNDERSTOOD TO BE AN AGREEMENT FOR SERVICES IN ACCORDANCE WITH THE CONDITIONS LISTED ON THE BACK OF THIS FORM. BY SIGNING "RELIQUISHED BY" YOU AGREE TO THESE TERMS AND CONDITIONS.

www.columbialaboratories.com





Report Number: 20-002237/D04.R00 **Report Date:** 03/04/2020 **ORELAP#:** OR100028 **Purchase Order: Received:** 02/26/20 11:00

Revision: 1.00 Document Control: CF001 Revision Date: 04/28/2018 Effective Date: 04/28/2018

 \sim

	PIXIS Labs CHAIN OF CUSTODY INSTRUCTIONS
COMPANY NAME	Name of the company and/or individual who will receive the lab report. Please specify if the billing information is
and CONTACT INFO -	different than the reporting information.
COMMENTS -	A brief description of any special instructions pertaining to the samples or reporting.
PO# -	Applies to a customer purchase order or number to be listed on the invoice.
PROJECT -	Applies to a customer project name or number to be listed on the report.
STATE COMPLIANCE -	Applies to report format. MUST BE CHECKED FOR ALL COMPLIANCE WORK REQUESTED. All samples must be collected and preserved properly. A job may be rejected if it does not meet State or NELAC standards. Refer to sampling instruction sheets.
CLIENT SAMPLE ID -	A short description of the sample point or material to be analyzed (e.g., "Effluent from sand filter"). This description will appear on the report.
COLLECTION DATE -	The date on which the sample(s) was/were collected.
COLLECTION TIME -	The time at which the sample(s) was/were collected.
SAMPLE TYPE -	This is a description of the sample media (e.g., drinking water, waste water, soil, etc.)
TESTING REQUESTED -	Use one line for each analysis or group of analyses associated to a specific sample ID.
SAMPLED BY -	The name of the person who collected the sample(s).
RELINQUISHED BY -	The signature of the person who is turning possession of the sample(s) to the lab for analysis along with date and time. All
	below terms and conditions are agreed upon this signature.
RECEIVED BY -	The lab personnel who receives the sample(s) signs here and fills in the date/time received. The date and time should be same as "Relinquished by" unless the sample(s) was shipped.

DIVIC Labo

TERMS AND CONDITIONS

PRICING AND CHARGES

PRICING AND CHARGES Prices to be charged for work performed for CUSTOMER are those currently published in the Columbia Food Laboratories, Inc. DBA Pixis Labs (herein referred to as "the LAB", where Columbia Food Laboratories, Inc. & Pixis Labs can be used interchangeably) standard price book unless otherwise agreed in writing by the CUSTOMER and the LAB. CUSTOMER must notify the LAB of price quotation at the time of the transfer of sample(s) to the LAB. Any cancellation of testing requirements will result in charges being assessed on all testing completed prior to the notice of cancellation. Unless otherwise agreed upon, samples containing hazardous material will be shipped back to client at their expense, or disposed of at a certain fee, waste category dependent. New accounts are accepted with full payment in advance by cash, check, Visa or Mastercard. A credit line may be established with an approved credit application.

DELIVERY AND LIABILITY LIMITATIONS

DELIVENT AND LABILITY LIMITATIONS The specific format of the goods will be defined by CUSTOMER to the LAB upon delivery of the sample(s) to the LAB. The LAB will analyze samples provided by CUSTOMER as requested by CUSTOMER in accordance with the procedures documented in the Quality Assurance Plan (QAP). Samples are retained for 15 days. If additional time is desired, then a written request is required and an additional monthly fee will apply. This price quote is only valid for one year after initial quote date.

CONFIDENTIALITY The LAB will treat all information regarding work performed for CUSTOMER as proprietary and confidential. No CUSTOMER information will be released to third persons without the written request of the CUSTOMER.

LIMITATION OF LIABILITY AND WARRANTY The LAB gives no warranty, express or implied, or of fitness for a particular purpose, in connection with its analytical testing or reporting. Any liability of the LAB to CUSTOMER or any third party shall be limited to the cost of analysis charged to CUSTOMER.

PAST DUE ACCOUNTS

Credit line account are payable within 30 days. Accounts that are 60 days past due will incur 1 1/2% per month on all past due sums until paid in full and will automatically default to cash on delivery (COD). Reports will not be released unless payment on past and current invoices are received. Customer agrees to pay the interest as a service charge and all the LAB's collection costs, including reasonable attorney fees.

EXPERT TESTIMONY AND COURT APPEARANCES

In the event CUSTOMER requires the further written opinion or testimony of any employee of the LAB, including response to a subpoena issued by CUSTOMER or any third person, CUSTOMER agrees to pay such additional fees and expenses as may be reasonably assessed by the LAB.

ALTERNATIVE DISPUTE RESOLUTION (ADR)

Any disputes arising out of this Agreement or the analytical testing or reporting by the LAB shall be settled through mediation and/or arbitration rather than litigation, and the cost of the ADR shall be borne equally by both parties.

APPLICABLE LAW Legal matters arising from work performed by the LAB for CUSTOMER will be construed and interpreted in accordance with the laws for the state of Oregon.

www.columbialaboratories.com

Page 6 of 12

Columbia LABORATORIES (A Tentamus Company	12423 NE Whit Portland, OR 503-254-1	97230	ау		Report Number: Report Date: ORELAP#: Purchase Order: Received:	20-002237/D04.R00 03/04/2020 OR100028 02/26/20 11:00
	umbia Food/Pixis Lab ample Receipt Form	S			ument Control: CF015 Effective: 05/11/2019	
Job Number: 20-002237	Search Name:					
Package/Cooler opened on (if different than received of	late/time) Date: 26 -20	Time:	11:00			
Received By (Initials):	U U					
 Were custody seals on outside of the package/cool If YES, how many and where? 		YES	NO	NA		
Were signature and date correct?		YES	NO	NA		
2) Were custody papers included in the package/cool	er?	YES	NO	NA		
3) Were custody papers properly filled out (ink, sign	, date)?	YES	NO	NA		
4) Did you sign custody papers in the appropriate pla	ice?	YES	NO	NA		
5) How was the package/cooler delivered?						
UPS FEDEX USPS CL	IENT COURIER	OTHE	R:			
Tracking Number (written in or copy of shipping	g label): 12 739	WVI	01	1259	7875	
6) Was packing material used?		YES	NO	NA		
Peanuts Bubble Wrap Foam Paper Oth	ner:					
7) Was sufficient ice used (if appropriate)? What kind?		YES	NO	NA		
	y Ice					
8) Were all sample containers sealed in separate plas		YĘS	NO	NA		
 Did all sample containers arrive in good condition 	0	YES	NO	NA		
10) Were all sample container labels complete?		VES	NO	NA		
11) Did all sample container labels and tags agree with	n the coc?	YES	NO	NA		
12) Were correct sample containers used for the tests		YES	NO	NA		
13) Were VOA vials checked for absence of air bubbl	es (note if found)?	YES	NO	NA		
14) Was a sufficient amount of sample sent in each sa	mple container?	YES	NO	NA		
15) Temperature of the samples upon receipt (See SO	P for proper temps)	20.	} ℃			
16) Sample location prior to login: R25 R39 R4	4 F44 Ambient Shelf	Canna	bis Tab	Other:		
Explain any discrepancies:				501		

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

Page _ 2_ of _ 2_





 Report Number:
 20-002237/D04.R00

 Report Date:
 03/04/2020

 ORELAP#:
 OR100028

 Purchase Order:
 20-002237/D04.R00

 Received:
 02/26/20 11:00

Revision: 1.00 Control: CFL-C21 Revised: 08/12/2019 Effective: 08/15/2019

AOAC 2007.1 & EN 1566. Memod Blank		Units: mg/Kg Batch ID: 200193 Laboratory Control Sample											
	Blank Result	Blank Limits	Notes	LCS Result	LCS Spike	LCS % Rec Limits Note							
Analyte Acephate	0.000	< 0.200	Notes	0.779	1 1.000	1 77.9	1693 - 129	Notes					
Acequinocyl	0.065	< 1.000		3.894	4.000	97.3	69.8 - 130	<u> </u>					
Acetamiprid	0.000	< 0.100	-	0.389	0.400	97.2	70.3 - 131						
Aldicarb	0.000	< 0.200		0.383	0.400	96.0	70.3 - 131	I					
Abamectin	0.053	< 0.288		0.768	1.000	94.7	70.5 - 131	<u> </u>					
Azoxystrobin	0.053	< 0.100		0.384	0.400	94.7	70.5 - 131	L					
Bifenazate	0.011	< 0.100		0.384	0.400	99.0		ļ					
Bifenthrin	0.012	< 0.100		0.397	0.400	99.3	71.3 - 132	<u> </u>					
Boscalid	0.012	< 0.100		0.848	0.400	106.0	70.7 - 131	<u> </u>					
Carbaryl	0.021	< 0.100		0.382	0.400	95.4		<u> </u>					
Carbofuran	0.004	< 0.100	1	0.382	0.400	95.4	70.8 - 132	<u> </u>					
				0.397				<u> </u>					
Chlorantraniliprol	0.010	< 0.100			0.400	96.3 128.0		I					
Chlorfenapyr	0.332	< 1.000	1	2.560	2.000								
Chlorpyrifos	0.000	< 0.100	1	0.364	0.400	90.9	71.2 - 132	L					
Clofentezine	0.011	< 0.100		0.375	0.400	93.9	68.1 - 126						
Cyfluthrin	0.103	< 1.000	1	2.166	2.000	108.3	70.5 - 131	ļ					
Cypermethrin	0.135	< 1.000	1	1.938	2.000	96.9	72.2 - 134						
Daminozide	0.000	< 1.000	1	2.007	2.000	100.3	68.1 - 127						
Diazinon	0.010	< 0.100	1	0.384	0.400	96.1	70.9 - 132						
Dichlorvos	0.000	< 0.500	1	2.057	2.000	102.9	69.1 - 128						
Dimethoat	0.007	< 0.100	1	0.385	0.400	96.4	70.1 - 130						
Ethoprophos	0.009	< 0.100	1	0.393	0.400	98.3	68.6 - 127						
Etofenprox	0.001	< 0.100	1	0.791	0.800	98.9	73.6 - 137						
Etoxazol	0.011	< 0.100		0.376	0.400	93.9	71.3 - 132						
Fenoxycarb	0.003	< 0.100	1	0.390	0.400	97.5	70.9 - 132						
Fenpyroximat	0.016	< 0.100		0.781	0.800	97.6	71.8 - 133						
Fipronil	0.028	< 0.100	1	0.771	0.800	96.4	71.2 - 132						
Flonicamid	0.062	< 0.400	1	0.984	1.000	98.4	69.4 - 129						
Fludioxonil	0.000	< 0.100	1	0.912	0.800	114.0	73.5 - 137	1					
Hexythiazox	0.022	< 0.400	1	0.930	1.000	93.0	71.7 - 133						
Imazalil	0.016	< 0.100	1	0.394	0.400	98.6	72.9 - 135						
Imidacloprid	0.039	< 0.200	1	0.758	0.800	94.7	69.9 - 130						
Kresoxim-Methyl	0.000	< 0.100	1	0.865	0.800	108.1	71.4 - 133	1					
Malathion	0.004	< 0.100	1	0.403	0.400	100.8	70.9 - 132						
Metalaxyl	0.007	< 0.100	1	0.389	0.400	97.4	70.5 - 131						
Methiocarb	0.004	< 0.100	1	0.387	0.400	96.6	70.8 - 132						
Methomyl	0.046	< 0.200	1	0.778	0.800	97.2	68.7 - 128						
MGK 264	0.013	< 0.100	1	0.404	0.400	100.9	70.6 - 131						
Myclobutanil	0.000	< 0.100	1	0.377	0.400	94.2	70.4 - 131						
Naled	0.026	< 0.200	1	0.982	1.000	98.2	71.6 - 133						
Oxamyl	0.000	< 0.400	1	2.005	2.000	100.3	68.5 - 127						
Paclobutrazol	0.005	< 0.200	1	0.773	0.800	96.6	71.6 - 133	1					
Parathion Methyl	0.000	< 0.200	1	0.794	0.800	99.3	71.8 - 133						
Permethrin	0.015	< 0.100	1	0.388	0.400	97.0	74.2 - 138	1					
Phosmet	0.006	< 0.100	1	0.393	0.400	98.2	71.0 - 132						
Piperonyl butoxide	0.000	< 1.000	1	2.099	2.000	104.9	75.3 - 140						
Prallethrin	0.035	< 0.200	1	0.372	0.400	92.9	71.9 - 134	I					
Propiconazole	0.000	< 0.200	1	0.782	0.800	97.7	70.9 - 132	-					
Propoxur	0.008	< 0.100	+	0.374	0.400	93.6	71.1 - 132						
Pyrethrins	0.008	< 0.500	+	0.360	0.413	87.1	74.8 - 139						
Pyridaben	0.000	< 0.100	+	0.379	0.410	94.9	78.0 - 145	-					
Spinosad	0.001	< 0.100	+	0.405	0.388	104.4	74.3 - 138						
Spiromesifen	0.001	< 0.100	+	0.403	0.400	104.4	71.5 - 133						
Spirotetramat	0.010	< 0.100	+	0.408	0.400	102.0	70.1 - 130						
Spiroxamine	0.010	< 0.100		0.401	0.400	98.8	70.1 - 130						
Tebuconazol	0.026	< 0.200		0.791	0.800	101.2							
Thiacloprid	0.000	< 0.100		0.388	0.400	96.9	71.1 - 132	<u> </u>					
Thiamethoxam	0.030	< 0.100	1	0.388	0.400	108.5	69.9 - 130	-					
Trifloxystrobin	0.000	< 0.100		0.434	0.400	99.9	71.5 - 133						

Laboratory Pesticide Quality Control Results Units: me/Ke Batch ID

www.columbialaboratories.com





 Report Number:
 20-002237/D04.R00

 Report Date:
 03/04/2020

 ORELAP#:
 OR100028

 Purchase Order:
 20-002237/D04.R00

 Received:
 02/26/20 11:00

Revision: 1.00 Control: CFL-C21 Revised: 08/12/2019 Effective: 08/15/2019

AOAC 2007.1 & EN 15662 Units: mg/Kg Batch ID: 2001936 Matrix Spike/Matrix Spike Duplicate Recoveries Sample ID: 20-002023-0007										
Analyte	Result	MS Res	MSD Res	Spike	RPD%	Limit		MSD % Rec	Limits	Notes
Acephate	0.000	1 0.807	0.811	1.000	0.6	1 < 30	80.7	81.1	50 - 150	1
Acequinocyl	0.000	4.331	4.438	4.000	2.5	< 30	108.3	111.0	50 - 150	
Acetamiprid	0.000	0.402	0.386	0.400	3.9	< 30	100.4	96.6	50 - 150	
Aldicarb	0.000	0.795	0.791	0.800	0.4	< 30	99.4	98.9	50 - 150	
Abamectin	0.046	1.043	1.019	1.000	2.3	< 30	99.7	97.3	50 - 150	-
Azoxystrobin	0.009	0.365	0.360	0.400	1.6	< 30	89.0	87.6	50 - 150	
Bifenazate	0.010	0.374	0.377	0.400	0.9	< 30	91.1	91.9	50 - 150	-
Bifenthrin	0.025	0.827	0.821	0.400	0.8	< 30	200.7	199.1	50 - 150	Q1
Boscalid	0.022	0.791	0.850	0.800	7.2	< 30	96.0	103.4	50 - 150	-
Carbaryl	0.013	0.394	0.389	0.400	1.3	< 30	95.2	94.0	50 - 150	
Carbofuran	0.004	0.398	0.399	0.400	0.3	< 30	98.5	98.8	50 - 150	
Chlorantraniliprol	0.008	0.359	0.370	0.400	3.1	< 30	87.7	90.5	50 - 150	
Chlorfenapyr	0.000	2.214	1.818	2.000	19.6	< 30	110.7	90.9	50 - 150	
Chlorpyrifos	0.007	0.462	0.436	0.400	6.0	< 30	113.9	107.2	50 - 150	
Clofentezine	0.010	0.428	0.410	0.400	4.2	< 30	104.6	100.2	50 - 150	
Cyfluthrin	0.082	1.664	1.742	2.000	4.5	< 30	79.1	83.0	30 - 150	
Cypermethrin	0.112	2.101	2.170	2.000	3.2	< 30	99.4	102.9	50 - 150	
Daminozide	0.000	1.756	1.701	2.000	3.1	< 30	87.8	85.1	30 - 150	
Diazinon	0.009	0.408	0.399	0.400	2.3	< 30	99.9	97.6	50 - 150	-
Dichlorvos	0.001	2.111	2.172	2.000	2.8	< 30	105.5	108.6	50 - 150	
Dimethoat	0.006	0.387	0.391	0.400	1.0	< 30	95.2	96.2	50 - 150	-
Ethoprophos	0.038	0.433	0.433	0.400	0.0	< 30	98.8	98.8	50 - 150	
Etofenprox	0.005	0.865	0.843	0.800	2.5	< 30	107.5	104.9	50 - 150	<u> </u>
Etoxazol	0.004	0.429	0.393	0.400	8.7	< 30	106.2	97.3	50 - 150	-
Fenoxycarb	0.002	0.397	0.389	0.400	2.1	< 30	98.7	96.7	50 - 150	
Fenpyroximat	0.002	0.760	0.757	0.400	0.4	< 30	95.0	94.6	50 - 150	<u> </u>
Fipronil	0.027	0.854	0.815	0.800	4.7	< 30	103.4	98.4	50 - 150	
Flonicamid	0.052	0.981	0.973	1.000	0.8	< 30	92.9	92.1	50 - 150	
Fludioxonil	0.000	0.794	0.842	0.800	5.8	< 30	993	105.2	50 - 150	<u> </u>
Hexythiazox	0.025	1.371	1.350	1.000	1.6	< 30	134.6	132.5	50 - 150	
Imazalil	0.013	0.402	0.376	0.400	6.7	< 30	97.5	90.9	50 - 150	-
Imidacloprid	0.034	0.792	0.786	0.800	0.7	< 30	94.7	94.0	50 - 150	-
Kresoxim-Methyl	0.000	0.743	0.767	0.800	3.2	< 30	92.9	95.9	50 - 150	
Malathion	0.000	0.382	0.387	0.400	1.3	< 30	95.5	96.7	50 - 150	-
Metalaxyl	0.006	0.382	0.387	0.400	6.1	< 30	101.5	95.4	50 - 150	
Methiocarb	0.002	0.412	0.387	0.400	1.2	< 30	101.5	103.8	50 - 150	
Methomyl	0.002	0.412	0.417	0.400	2.6	< 30	91.7	89.2	50 - 150	
MGK 264	0.040	0.448	0.734	0.400	9.1	< 30	108.9	119.6	50 - 150	
Myclobutanil	0.013	0.392	0.491	0.400	2.4	1 < 30	98.1	95.7	50 - 150	
Naled	0.000	1.010	0.365	1.000	1.5	< 30	98.8	97.3	50 - 150	
Oxamyl	0.022	2.034	1.858	2.000	9.0	< 30	101.7	97.5	50 - 150	
Paclobutrazol	0.000	0.824	0.835	0.800	9.0	< 30	101.7	104.0	50 - 150	<u> </u>
Parathion Methyl	0.003	0.824	0.652	0.800	17.9	< 30	97.4	81.5	30 - 150	
Paratnion Metnyi Permethrin	0.000	0.780	0.652	0.400	17.9	< 30	116.0	81.5 117.3	<u>30</u> - 150 50 - 150	
Permeurin Phosmet	0.014	0.383	0.463	0.400	5.1	< 30	94.2	99.3	50 - 150	
Piperonyl butoxide	0.000	2.150	2.113	2.000	1.7	< 30	107.5	105.6	50 - 150	
Prallethrin	0.000	0.540	0.512	0.400	5.4	< 30	107.5	105.6	50 - 150	
Propiconazole	0.021	0.540	0.512	0.400	0.7	< 30	129.7	99.9	50 - 150	
Propiconazoie Propoxur	0.000	0.805	0.800	0.800	3.7	< 30	93.8	99.9	50 - 150	
Propoxur Pyrethrins	0.007	0.382	0.396	0.400	0.1	< 30	93.8	97.4	50 - 150	
		0.406	0.406	0.413	0.1	< 30	98.3 89.4	98.2 88.8		
Pyridaben	0.000	0.358	0.355	0.388	4.2	< 30	89.4		50 - 150	
Spinosad	0.000							112.7		
Spiromesifen	0.011	0.466	0.496	0.400	6.2	< 30	113.8	121.3		
Spirotetramat	0.000	0.362	0.343	0.400	5.4	< 30	90.5	85.8	50 - 150	L
Spiroxamine	0.022	0.777	0.787	0.800	1.3	< 30	94.4	95.7	50 - 150	1
Febuconazol	0.034	0.793	0.820	0.800	3.3	< 30	94.9	98.3	50 - 150	
l hiacloprid	0.000	0.391	0.389	0.400	0.4	< 30	97.7	97.3	50 - 150	
Thiamethoxam	0.028	0.413	0.378	0.400	8.8	< 30	96.3	87.5	50 - 150	
Trifloxystrobin	0.000	0.408	0.401	0.400	1.1	< 30	101.9	100.2	50 - 150	

Laborator	Pesticide Quality	Control Results
Laborator	resticiue Quality	control Results

www.columbialaboratories.com





 Report Number:
 20-002237/D04.R00

 Report Date:
 03/04/2020

 ORELAP#:
 OR100028

 Purchase Order:
 20-002237/D04.R00

 Received:
 02/26/20 11:00

Revision #: 0.00 Control : CFL-D06 Revision Date: 05/31/2019 Effective Date: 05/31/2019

Laboratory Quality Control Results								
J AOAC 2015	V98-6							
Laboratory Control Sample								
Analyte	Result		Spike	Units	% Rec	Limits	Evaluation	Notes
CBDV-A	0.194		0.2	%	97.2	85.0 - 1	15 Acceptable	
CBDV	0.212		0.2	%	106	85.0 - 1	15 Acceptable	
CBD-A	0.194		0.2	%	97.1	85.0 - 1	15 Acceptable	
CBG-A	0.203		0.2	%	102	85.0 - 1	15 Acceptable	
CBG	0.202		0.2	%	101	85.0 - 1	15 Acceptable	
CBD	0.188		0.2	%	93.8	85.0 - 1	15 Acceptable	
THCV	0.196		0.2	%	97.8	85.0 - 1	15 Acceptable	
THCVA	0.196		0.2	%	97.9	85.0 - 1	15 Acceptable	
CBN	0.186		0.2	%	93.2	85.0 - 1	15 Acceptable	
тнс	0.195		0.2	%	97.4	85.0 - 1	15 Acceptable	
D8THC	0.188		0.2	%	94.2	85.0 - 1	15 Acceptable	
CBL	0.192		0.2	%	96.1	85.0 - 1	15 Acceptable	
CBC	0.198		0.2	%	98.9	85.0 - 1	15 Acceptable	
THCA	0.186		0.2	%	93.2	85.0 - 1	15 Acceptable	
CBCA	0.189		0.2	%	94.5	85.0 - 1	15 Acceptable	

Method Blank

Analyte	Result	LOQ	Units	Limits	Evaluation	Notes
CBDV-A	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBDV	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBD-A	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBG-A	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBG	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBD	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
THCV	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
THCVA	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBN	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
тнс	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
D8THC	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBL	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBC	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
THCA	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBCA	<loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	

Abbreviations

ND - None Detected at or above MRL

RPD - Relative Percent Difference

LOQ - Limit of Quantitation

Units of Measure:

% - Percent

www.columbialaboratories.com





 Report Number:
 20-002237/D04.R00

 Report Date:
 03/04/2020

 ORELAP#:
 OR100028

 Purchase Order:
 20-002237/D04.R00

 Received:
 02/26/20 11:00

Revision #: 0.00 Control : CFL-D06 Revision Date: 05/31/2019 Effective Date: 05/31/2019

	Laboratory Quality Control Results									
J AOAC 2015 V9	98-6									
Sample Duplicat	te		Sample ID: 20-002237-0001							
Analyte	Result	Org. Result	Org. Result LOQ Units RPD Limits Evaluation Notes							
CBDV-A	0.181	0.177	0.1	%	2.28	< 20	Acceptable			
CBDV	0.232	0.227	0.1	%	2.37	< 20	Acceptable			
CBD-A	42.1	40.8	0.1	%	3.35	< 20	Acceptable			
CBG-A	1.02	0.998	0.1	%	2.37	< 20	Acceptable			
CBG	0.440	0.431	0.1	%	2.08	< 20	Acceptable			
CBD	55.6	53.8	0.1	%	3.32	< 20	Acceptable			
THCV	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			
THCVA	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			
CBN	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			
тнс	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			
D8THC	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			
CBL	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			
CBC	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			
THCA	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			
CBCA	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable			

Abbreviations

- ND None Detected at or above MRL
- RPD Relative Percent Difference
- LOQ Limit of Quantitation
- NA Calculation Not Applicable given non-numerical results

Units of Measure:

% - Percent

www.columbialaboratories.com

Page 11 of 12





 Report Number:
 20-002237/D04.R00

 Report Date:
 03/04/2020

 ORELAP#:
 OR100028

 Purchase Order:
 20-002237/D04.R00

 Received:
 02/26/20 11:00

Explanation of QC Flag Comments:

Code	Explanation
Q	Matrix interferences affecting spike or surrogate recoveries.
Q1	Quality control result biased high. Only non-detect samples reported.
Q2	Quality control outside QC limits. Data considered estimate.
Q3	Sample concentration greater than four times the amount spiked.
Q4	Non-homogenous sample matrix, affecting RPD result and/or % recoveries.
Q5	Spike results above calibration curve.
Q6	Quality control outside QC limits. Data acceptable based on remaining QC.
R	Relative percent difference (RPD) outside control limit.
R1	RPD non-calculable, as sample or duplicate results are less than five times the LOQ.
R2	Sample replicates RPD non-calculable, as only one replicate is within the analytical range.
LOQ1	Quantitation level raised due to low sample volume and/or dilution.
LOQ2	Quantitaion level raised due to matrix interference.
В	Analyte detected in method blank, but not in associated samples.
B1	The sample concentration is greater than 5 times the blank concentration.
B2	The sample concentration is less than 5 times the blank concentration.

www.columbialaboratories.com